ABSTRACT
INTRODUCTION: Investigation for obstructive sleep apnea syndrome (OSAS) is mandatory before bariatric surgery. Data regarding chronic insomnia and chronic sleep deprivation are scarce in this population. METHODS: A cross-sectional study assessing the prevalence of chronic insomnia, OSAS and chronic sleep privation in an obese population referred for bariatric surgery. RESULTS: In all, 88 patients (74% women, median age 41 [33.5-50] years and median body mass index 42 [39.2-45.7] kg/m2) were included. The prevalence of chronic insomnia was 31% in the 87% suffering from OSAS that required continuous positive airway pressure therapy. Comorbid insomnia and sleep apnoea (COMISA) were found in 27% of our population. Chronic insomnia was associated with a lower quality of life (median EQ5D analogue visual scale: 60 [50-70] P=0.04) and a poor sleep quality (median Pittsburgh sleep quality index (PSQI): 8 (6-11 P<0.01) The deleterious combination of sleep privation and insomnia had a higher impact in terms of impairment of quality of life and sleep quality (median EQ5D analogue visual scale: 50 [40-65] P=0.02 et median PSQI: 11 [9-14, P<0.01) CONCLUSION: Chronic insomnia and sleep privation have synergistic deleterious effects in candidates for bariatric surgery. Further studies need to be conducted to evaluate the evolution after surgery.
Subject(s)
Bariatric Surgery , Quality of Life , Adult , Continuous Positive Airway Pressure , Cross-Sectional Studies , Female , Humans , Male , SleepABSTRACT
Most of the continuous positive airway pressure (CPAP) devices currently in use allow telemonitoring of observance, leaks and the apnoea-hypopnoea index (AHI). La Société française de recherche et de médecine du sommeil (SFRMS) and La Société de pneumologie de langue française (SPLF) workgroup offer to CPAP prescribers and to home care providers a scientific document which has the following purposes: to underline the relevance of the telemonitoring of leaks and the AHI, to define alert thresholds, to describe the principal mechanisms generating excessive leaks and high AHI, and to propose a diagnostic algorithm.
Subject(s)
Algorithms , Continuous Positive Airway Pressure , Monitoring, Physiologic , Pulmonary Medicine/standards , Sleep Apnea, Obstructive/therapy , Telemedicine/standards , Continuous Positive Airway Pressure/instrumentation , Continuous Positive Airway Pressure/methods , Continuous Positive Airway Pressure/standards , France , Home Care Services/organization & administration , Humans , Medical Order Entry Systems/organization & administration , Medical Order Entry Systems/standards , Monitoring, Physiologic/methods , Monitoring, Physiologic/standards , Patient Compliance , Prognosis , Pulmonary Medicine/methods , Pulmonary Medicine/organization & administration , Reference Values , Sleep Apnea, Obstructive/diagnosis , Sleep Apnea, Obstructive/epidemiology , Societies, Medical/organization & administration , Societies, Medical/standards , Telemedicine/methodsABSTRACT
The preliminary results of the SERVE-HF study have led to the release of safety information with subsequent contraindication to the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnoeas in patients with chronic symptomatic systolic heart failure with left ventricular ejection fraction (LVEF) ≤ 45%. The aim of this article is to review these results, and to provide more detailed arguments based on data from the literature advocating the continued use of ASV in different indications, including heart failure with preserved LVEF, complex sleep apnoea syndrome, opioid-induced central sleep apnea syndrome, idiopathic central SAS, and central SAS due to a stroke. Based on these findings, we propose to set up registers dedicated to patients in whom ASV has been stopped and in the context of the next setting up of ASV in these specific indications to ensure patient safety and allow reasoned decisions on the use of ASV.
Subject(s)
Respiration, Artificial/methods , Sleep Apnea, Central/therapy , Expert Testimony , Heart Failure/etiology , Heart Failure/prevention & control , Humans , Sleep Apnea, Central/complicationsSubject(s)
Electrocoagulation/methods , Lung Diseases/therapy , Airway Obstruction/therapy , Bronchoscopy , HumansABSTRACT
Proteoglycans that modulate the activities of growth factors, chemokines, and coagulation factors regulate in turn the vascular endothelium with respect to processes such as inflammation, hemostasis, and angiogenesis. Endothelial cell-specific molecule-1 is mainly expressed by endothelial cells and regulated by pro-inflammatory cytokines (Lassalle, P., Molet, S., Janin, A., Heyden, J. V., Tavernier, J., Fiers, W., Devos, R., and Tonnel, A. B. (1996) J. Biol. Chem. 271, 20458-20464). We demonstrate that this molecule is secreted as a soluble dermatan sulfate (DS) proteoglycan. This proteoglycan represents the major form either secreted by cell lines or circulating in the human bloodstream. Because this proteoglycan is specifically secreted by endothelial cells, we propose to name it endocan. The glycosaminoglycan component of endocan consists of a single DS chain covalently attached to serine 137. Endocan dose-dependently increased the hepatocyte growth factor/scatter factor (HGF/SF)-mediated proliferation of human embryonic kidney cells, whereas the nonglycanated form of endocan did not. Moreover, DS chains purified from endocan mimicked the endocan-mediated increase of cell proliferation in the presence of HGF/SF. Overall, our results demonstrate that endocan is a novel soluble dermatan sulfate proteoglycan produced by endothelial cells. Endocan regulates HGF/SF-mediated mitogenic activity and may support the function of HGF/SF not only in embryogenesis and tissue repair after injury but also in tumor progression.
Subject(s)
Hepatocyte Growth Factor/physiology , Mitogens/physiology , Neoplasm Proteins , Proteoglycans/physiology , Amino Acid Sequence , Animals , Blood Coagulation/physiology , CHO Cells , Cell Line , Chondroitinases and Chondroitin Lyases/metabolism , Chromatography, Gel , Cricetinae , Glycosylation , Humans , Molecular Weight , Polysaccharide-Lyases/metabolism , Proteoglycans/chemistrySubject(s)
Burns/pathology , Fires , Lung/pathology , Adult , Female , Humans , Inhalation , Lung Injury , Male , Petroleum/adverse effects , PrognosisABSTRACT
ICAMs are ligands for LFA-1, a major integrin of mononuclear cells involved in the immune and inflammatory processes. We previously showed that endothelial cell specific molecule-1 (ESM-1) is a proteoglycan secreted by endothelial cells under the control of inflammatory cytokines. Here, we demonstrate that ESM-1 binds directly to LFA-1 onto the cell surface of human blood lymphocytes, monocytes, and Jurkat cells. The binding of ESM-1 was equally dependent on Ca(2+), Mg(2+), or Mn(2+) divalent ions, which are specific, saturable, and sensitive to temperature. An anti-CD11a mAb or PMA induced a transient increase in binding, peaking 5 min after activation. Direct binding of ESM-1 to LFA-1 integrin was demonstrated by specific coimmunoprecipitation by CD11a and CD18 mAbs. A cell-free system using a Biacore biosensor confirmed that ESM-1 and LFA-1 dynamically interacted in real time with high affinity (K(d) = 18.7 nM). ESM-1 consistently inhibited the specific binding of soluble ICAM-1 to Jurkat cells in a dose-dependent manner. These results suggest that ESM-1 and ICAM-1 interact with LFA-1 on binding sites very close to but distinct from the I domain of CD11a. Through this mechanism, ESM-1 could be implicated in the regulation of the LFA-1/ICAM-1 pathway and may therefore influence both the recruitment of circulating lymphocytes to inflammatory sites and LFA-1-dependent leukocyte adhesion and activation.
Subject(s)
CD18 Antigens/metabolism , Endothelium, Vascular/physiology , Intercellular Adhesion Molecule-1/metabolism , Lymphocyte Function-Associated Antigen-1/metabolism , Neoplasm Proteins , Proteins/metabolism , Proteoglycans , Biosensing Techniques , Cell Adhesion/physiology , Cell Movement/physiology , Cell-Free System , Computer Systems , Humans , Inflammation , Jurkat Cells/metabolism , Lymphocyte Activation/physiology , Protein Binding/drug effects , Protein Structure, Tertiary , Proteins/pharmacology , Temperature , Tetradecanoylphorbol Acetate/pharmacologyABSTRACT
Dermatomyositis, an inflammatory muscle disease probably related to dysimmunity, is associated with character skin eruptions. Dermatomyositis is often associated with cancer (15 to 40% of cases depending on the series). All histological types and all cancer localizations observed in the general population can be associated with dermatomyositis. We report the case of a patient with dermatomyositis who developed small-cell lung cancer. There have been few descriptions of this association in the literature. Certain clinical features of dermatomyositis would be predictive of its paraneoplastic nature. Prognosis is very poor. Treatment is basically dictated by the underlying neoplasia.